Since O6MeG induced by TMZ (and other methylating anticancer drugs) is a toxic DNA damage, it is understandable that MGMT deficiency (determined, e.g., by promoter methylation) leads to responsiveness of the tumor [25,26]. Here, MGMT is linked to neoplasm.